SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Pathways (CLPA)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fred Mussler who wrote (236)10/3/1999 2:51:00 AM
From: Neuroguy  Read Replies (1) of 566
 
Fred - RB is definitely were it all happens for CLPA, as far as message boards go. KBFLY started this thread, but few of us SIers that are into CLPA waste our time here. The Raging Bull board is the best place for info on this company by far. If that board has a problem, it might be deemed to be dominated by longs. As one myself (I'm "trav007" there), I see no problemo...:) But forwarned is forearmed and all that.

If you or anyone else wants a quick FAQs sheet on the compamy, I suggest:
ragingbull.com

Very to the point. Does this company have one of the huge big discoveries in the cancer field? Yes. Read the FAQs. They have identified a novel cellular pathway expressed only in cancer cells whose inhibition makes cancer cells commit hari kari (apoptosis).. The effect of the drugs is specific to cancer cells because the enzyme they target is only expressed significantly in those cells. Hence neglible side effects of the drug. Moreover, because they act via a common ultimate endpoint, but different route than traditional chemos and radiation, they allow these treatments to be given at vastly lower (subtherapeutic) does. Imagine the improvement in a patient's life!! As a result, Rhone Polenc (RP) have initiated joint clinical trials with their lead taxane, taxomere.
This is absolutely one of the hottest biotechs I know of. Their stock price is depressed partly because of a miscue on their initial phase III trial (not related to the effectiveness of the drug - see the links), and because the short interest skyrocketed - currently almost 20% of the float. The shorts parrot the line "the drug was no better than placebo", which sounds fine, until you understand the drug actually worked, but there were problems with the placebo group. A detailed explanation of the Phase III trial is given at:
ragingbull.com

The bottom line is that we are looking at a class of compounds that have a general effect on cancers of most types that have virtually NO side effects. Sound too good to be true? Yes - so read the links. They should explain.

Other useful links are given at:
ragingbull.com
and the Technology page from the company at:
cellpathways.com

If you have further questions, feel free to email me at trav@ragingbull.com. I can try and point you to the best sites here.

Enjoy!

NeuroDude
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext